Consensus Tarsus Pharmaceuticals, Inc.

Stocks

TARS

US87650L1035

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 28/08/2026 +03			5-day change	1st Jan Change
71.76 ^USD	-0.22%		-1.29%	-12.36%

08-12	Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating	MT
08-07	Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating	MT

Evolution of the Average Target: Tarsus Pharmaceuticals, Inc.

Evolution of the Target Price: Tarsus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Tarsus Pharmaceuticals, Inc.

c0b12b786020e15c328e486417.2VACQ88XaU2qptruZ0iywNb-QLYbJGREHjNGpzWDwJo.ixJmJftAIBTl8-2pVwX-sriEdoRoCRE3VUR1xQPFitjsaW9xqSFfOv3lsQ~53960c859e368bc072ee0323c15870ac

Analysts' recommendations: Tarsus Pharmaceuticals, Inc.

08-12	Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating	MT
08-07	Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating	MT
07-31	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating	MT
04-24	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating	MT
04-23	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $100 From $101, Keeps Outperform Rating	MT
03-26	Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating	MT
02-25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating	MT
11-20	Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target	MT
09/10/25	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
09/10/25	BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80	MT
06/08/25	Tarsus Pharmaceuticals Q2 revenue beats expectations	RE
02/06/25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating	MT
03/02/25	BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74	MT
22/01/25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating	MT
14/11/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	MT
09/08/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating	MT
09/05/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
29/02/24	Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	MT
28/02/24	Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	MT
20/11/23	Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	MT
10/11/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	MT
11/09/23	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	MT
11/08/23	HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	MT
26/07/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	MT
18/07/23	William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TARSUS PHARMACEUTICALS, INC.					+32.19%
	REGENERON PHARMACEUTICALS, INC.					+5.82%
	CSL LIMITED					-5.25%
	MODERNA, INC.					-22.73%
	SAMSUNG BIOLOGICS CO.,LTD.					+32.94%
	UCB					+31.76%
	BIOGEN INC.					+8.11%
	INCYTE CORPORATION					+2.22%
	INNOVENT BIOLOGICS, INC.					+19.54%
	SWEDISH ORPHAN BIOVITRUM AB					+6.73%
	Average					+11.13%
	Weighted average by Cap.					+7.80%